Biointron’s Q2 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in April, May, and June. This quarter, six novel antibody drugs have received first approval.
Pivekimab Sunirine (Decnupaz)
Anbenitamab (恩尼妥)
Gumokimab
Silevimig
Iza-bren
Veligrotug (Lumvoa)
Q2 2026 saw many acquisitions, collaborations, and licensing agreements for multiple assets (up to 13 at a time). Significant investment has been directed toward startups developing antibody-drug conjugates (ADCs). Antibody discovery with AI has become a large topic in research, as well as antibody formats such as ATP-switch antibodies.
Gain exclusive insights into current trends such as:
6 novel antibody drugs approved for the first time in Q2 2026
Top 20 antibody drug deals, including M&As, licensing agreements, and collaborations of up to US$15.2B
Antibody discovery in the AI era, from candidate sequences to model-ready experimental data
Conditionally activatable antibodies through specific biological or physical cues
A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q3 2026
Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events a……
When we think of antibodies, sharks and alpacas probably aren't the first an……
Antibody-based cancer therapies have expanded treatment options across multiple ……
Monoclonal antibodies (mAbs) are an established class of biopharmaceuticals, wit……
You can also contact us on the Scientist and Science Exchange marketplaces.